{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:31:08Z","timestamp":1769855468046,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Contracept Reprod Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The etonogestrel subdermal implant is the most efficacious hormonal contraceptive currently available and provides 99.7% effective contraception. However, similar to other hormonal contraception, its effectiveness is compromised with the use of cytochrome P450 inducing drugs resulting in an unplanned pregnancy. Despite this risk, little is known about the outcome of concomitant use of rifampin and contraceptive implants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 24-year-old woman was provided with an etonogestrel implant in September 2018. In July 2020, she was started with rifampin based anti-tuberculosis for tuberculosis of the lymph nodes. In December 2020, she presented to the family planning clinic of St. Paul\u2019s Hospital Millennium Medical college with a diagnosis of failed implant and second-trimester pregnancy at a gestational age of 19\u00a0weeks. The etonogestrel implant was removed and the patient was linked to antenatal care follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Concomitant use of hepatic cytochrome P450 enzyme-inducing medications with certain hormonal contraceptives may reduce effectiveness resulting in unintended pregnancy. Women should be given detailed counseling about the potential for drug interactions and a multidisciplinary approach with consultation or referral to reproductive health specialists is crucial for optimal management of women who are at increased risk of contraceptive failure and unintended pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40834-022-00172-1","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T23:28:37Z","timestamp":1651706917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Etonogestrel contraceptive implant failure in a woman taking rifampin: a case report"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8623-9113","authenticated-orcid":false,"given":"Tesfaye H.","family":"Tufa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Fessehaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferid A.","family":"Abubeker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"172_CR1","volume-title":"Family Planning: A Global Handbook for Providers (2018 update)","author":"World Health Organization Department of Reproductive Health and Research (WHO\/RHR)","year":"2018","unstructured":"World Health Organization Department of Reproductive Health and Research (WHO\/RHR), Johns Hopkins Bloomberg School of Public Health\/Center for Communication Programs (CCP), Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and WHO; 2018."},{"key":"172_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1783\/147118910793048629","volume":"36","author":"D Mansour","year":"2010","unstructured":"Mansour D. Nexplanon\u00ae: what Implanon\u00ae did next. J Fam Plann Reprod Health Care. 2010;36:187\u20139.","journal-title":"J Fam Plann Reprod Health Care"},{"key":"172_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0010-7824(01)00294-3","volume":"65","author":"HB Croxatto","year":"2002","unstructured":"Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception. 2002;65:21\u20137.","journal-title":"Contraception"},{"issue":"9","key":"172_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3109\/09513590.2011.652247","volume":"28","author":"S Palomba","year":"2012","unstructured":"Palomba S, Falbo A, Di Cello A, Materazzo C, Zullo F. Nexplanon: the new implant for long-term contraception. Compr Descriptive Rev, Gynecol Endocrinol. 2012;28(9):710\u201321.","journal-title":"Compr Descriptive Rev, Gynecol Endocrinol"},{"issue":"5","key":"172_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ajog.2012.08.002","volume":"207","author":"E Mommers","year":"2012","unstructured":"Mommers E, Blum G-F, Gent TG, Peters KP, Sordal TS, Marintcheva-Petrova M. Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial. Am J Obstet Gynecol. 2012;207(5):388-e6.","journal-title":"Am J Obstet Gynecol"},{"key":"172_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cts.12499","volume":"11","author":"N Zhang","year":"2018","unstructured":"Zhang N, Shon J, Kim M, Yu C, Zhang L, Huang S, et al. Role of CYP3A in Oral Contraceptives Clearance. Clin Transl Sci. 2018;11:251\u201360.","journal-title":"Clin Transl Sci"},{"key":"172_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OAJC.S12194","volume":"1","author":"B Gbolade","year":"2010","unstructured":"Gbolade B. Failure of Implanon\u00ae on antituberculous therapy. Open Access J Contracept. 2010;1:103\u20135. https:\/\/doi.org\/10.2147\/OAJC.S12194.","journal-title":"Open Access J Contracept."},{"issue":"4","key":"172_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00404-005-0064-4","volume":"273","author":"C Schindlbeck","year":"2006","unstructured":"Schindlbeck C, Janni W, Friese K. Failure of Implanon contraception in a patient taking carbamazepin for epilepsia. Arch Gynecol Obstet. 2006;273(4):255\u20136.","journal-title":"Arch Gynecol Obstet"},{"key":"172_CR9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.contraception.2011.09.005","volume":"85","author":"N Leticee","year":"2012","unstructured":"Leticee N, Viard JP, Yamgnane A, et al. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012;85:425\u20137.","journal-title":"Contraception"},{"key":"172_CR10","volume-title":"Contraceptive Technology, 21st revised edition","author":"J Trussell","year":"2018","unstructured":"Trussell J, Aiken ARA, et al. Contraceptive efficacy. In: Hatcher RA, et al., editors. Contraceptive Technology, 21st revised edition. New York: Ardent Media; 2018."},{"key":"172_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.contraception.2004.10.005","volume":"71","author":"M Harrison-Woolrych","year":"2005","unstructured":"Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception. 2005;71:306\u20138.","journal-title":"Contraception"},{"issue":"s1","key":"172_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/13625180801942754","volume":"13","author":"O Graesslin","year":"2008","unstructured":"Graesslin O, Korver T. The contraceptive efficacy of Implanon\u00ae: A review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13(s1):4\u201312.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"172_CR13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-1-4939-1233-9_20","volume-title":"Contraception for the medically challenging patient","author":"R Perry","year":"2014","unstructured":"Perry R, Stone RH, Haider S. Medication interactions with contraceptives. In: Allen RH, Cwiak CA, editors. Contraception for the medically challenging patient. New York: Springer Science + Business Media; 2014. p. 347\u201362."},{"key":"172_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.contraception.2017.03.004","volume":"95","author":"A Lazorwitz","year":"2017","unstructured":"Lazorwitz A, Davis A, Swartz M, Guiahi M. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users. Contraception. 2017;95:571\u20137.","journal-title":"Contraception"},{"issue":"12","key":"172_CR15","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1002\/ccr3.3156","volume":"8","author":"MT Kumbeni","year":"2020","unstructured":"Kumbeni MT, Apanga PA, Ayamga EA. Nexplanon failure in a woman with HIV infection in rural Ghana: A case report. Clin Case Rep. 2020;8(12):2369\u201372.","journal-title":"Clin Case Rep"},{"key":"172_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1752-1947-8-43","volume":"8","author":"J Lange","year":"2014","unstructured":"Lange J, Teal S, Tocce K. Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report. J Med Case Reports. 2014;8:43. https:\/\/doi.org\/10.1186\/1752-1947-8-43.","journal-title":"J Med Case Reports"},{"key":"172_CR17","unstructured":"World Health Organization. 2015 Medical Eligibility Criteria for Contraceptive Use. 5th Edition. Geneva: World Health Organization; 2015. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241549158 (Accessed on 24 Dec 2020)."},{"key":"172_CR18","volume-title":"US Medical Eligibility Criteria (US MEC) for contraceptive use","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. US Medical Eligibility Criteria (US MEC) for contraceptive use. USA: Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion; 2016."},{"key":"172_CR19","unstructured":"UKMEC April 2016 (Amended September 2019) - Faculty of Sexual and Reproductive Healthcare n.d. https:\/\/www.fsrh.org\/standards-and-guidance\/documents\/ukmec-2016\/ (Accessed 2 Jan 2021)."},{"key":"172_CR20","unstructured":"Drug Interactions - Faculty of Sexual and Reproductive Healthcare n.d. https:\/\/www.fsrh.org\/standards-and-guidance\/fsrh-guidelines-and-statements\/drug-interactions\/ (Accessed 2 Jan 2021)."},{"key":"172_CR21","unstructured":"Merck. Nexplanon Full Prescribing Information 2020. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/n\/nexplanon\/nexplanon_pi.pdf (Accessed Feb 2021)"}],"container-title":["Contraception and Reproductive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-022-00172-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40834-022-00172-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40834-022-00172-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T11:49:14Z","timestamp":1675511354000},"score":1,"resource":{"primary":{"URL":"https:\/\/contraceptionmedicine.biomedcentral.com\/articles\/10.1186\/s40834-022-00172-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["172"],"URL":"https:\/\/doi.org\/10.1186\/s40834-022-00172-1","relation":{},"ISSN":["2055-7426"],"issn-type":[{"value":"2055-7426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"12 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance was obtained from the Institutional Research and Ethics Review Committee (IRB) of St. Paul\u2019s Hospital Millennium Medical College for publication of the case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed and written consent was taken from the patient to publish the case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}